本帖最后由 老马 于 2012-1-13 21:20 编辑 ' K1 i1 ?* }% H; w6 }( H
/ L! Z3 F& |7 v爱必妥和阿瓦斯丁的比较; v( T! S) c: D5 W% K3 y6 Y
7 [ Z8 D9 o6 Z' F- }http://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 o3 D: v1 S/ P! U0 w
2 W6 E) ]/ }9 y+ ?8 K
* O9 D! Y4 ^0 `
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 y5 ?$ J8 j/ A$ t
==================================================
6 r: {! N# P1 y1 J' d4 S; uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 u p6 h3 d! WPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 |7 c2 v6 O: K2 eResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.; F, [+ [. G8 @+ y' I0 M2 H
|